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OutcomesAbstract Background: Although relatively rare, cancer in teenagers and young adults (TYA)
is the most common disease-related cause of death and makes a major contribution to years of
life lost in this age group. There is a growing awareness of the distinctive needs of this age
group and drive for greater understanding of how outcomes can be improved. We present here
the latest TYA survival trends data for the United Kingdom (UK).
Methods: Using national cancer registry data, we calculated ﬁve-year relative survival for all
15–24 year olds diagnosed with cancer or a borderline/benign CNS tumour in the UK during
the periods 1992–1996, 1997–2001 and 2002–2006. We analysed trends in survival for all can-
cers combined and for eighteen speciﬁed groups that together represent the majority of TYA
cancers. We compared our data with published data for Europe, North America and
Australia.
Results: Five-year survival for all cancers combined increased from 75.5% in 1992–1996 to
82.2% in 2002–2006 (P < 0.001). Statistically signiﬁcant improvements were seen for all dis-
ease groups except osteosarcoma, rhabdomyosarcoma, non-gonadal and ovarian germ cell
tumours and ovarian and thyroid carcinomas. During the earliest time period, females had sig-
niﬁcantly better survival than males for ﬁve of the twelve non-gender-speciﬁc disease groups.
By the latest period, only melanomas and non-rhabdomyosarcoma soft tissue sarcomas had
2040 C. O’Hara et al. / European Journal of Cancer 51 (2015) 2039–2048differential survival by gender. Survival in the UK for the most recent period was generally
similar to other comparable countries.
Conclusion: Five-year survival has improved considerably in the UK for most cancer types.
For some disease groups, there has been little progress, either because survival already
approaches 100% (e.g. thyroid carcinomas) or, more worryingly for some cancers with poor
outcomes, because they remain resistant to existing therapy (e.g. rhabdomyosarcoma). In
addition, for a number of speciﬁc cancer types and for cancer as a whole males continue to
have worse outcomes than females.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Teenage and young adult (TYA) patients represent
an important and distinct group within the overall pop-
ulation of cancer patients. Cancer is the most common
cause of non-accidental death in 13–29 year olds [1]
and makes a major contribution to years of life lost in
this age group, with substantial economic consequences.
There is now growing clinical awareness of the distinc-
tive care needs of this age group and a concern that
improvements in survival rates appear to be slower for
TYA than for children and adults aged 45 years and
older [2]. Moreover, low participation in clinical trials
is impeding the development of optimal therapies for
this age group [3,4].
Successive Eurocare projects have provided data on
cancer survival in Europe by sub-region, including the
United Kingdom (UK) and its constituent countries
[5]. However, the latest TYA data reported are for
patients diagnosed up to 2002. Survival data for
England were also published in 2008 [6], for patients
diagnosed up to 2001. More contemporary survival
rates for adolescent and young adult cancer patients
have been reported for several single European countries
(e.g. [7–9] and for the United States (USA) [10]).
Since clinical trial enrolment is not the norm in this
age group, and for many patients no suitable trials are
available, there is a demand for clinical outcomes to
be monitored using contemporary national data. We
present here the most recent TYA survival data with
mature follow up for the whole of the UK, for eighteen
types of cancer that together represent 92% of all cancer
diagnoses in the 15–24 year age group. We also compare
our survival rates and trends for the UK with the most
recent published data from other countries.
In the last decade, Clinical Service Guidance (CSG)
for services for children, teenagers and young adults
with cancer have been issued for England and Wales
[11]. Specialised TYA Principal Treatment Centres have
been established to oversee the care of TYA cancer
patients, alongside more local TYA Designated Units
for older TYA patients who choose to be treated closer
to home. Our data largely pre-date the implementation
of these guidelines. Therefore, in addition to showing
the rate of improvement prior to the implementationof the CSG, we provide an important baseline esti-
mate from which the eﬀects of the implementation of
national guidance can be evaluated and future interna-
tional comparisons made.
2. Methods
Information on 25,658 patients aged 15–24 years
diagnosed between 1992 and 2006 in the United
Kingdom with a malignancy or a borderline/benign
CNS tumour (such as pilocytic astrocytoma or schwan-
noma) was extracted from the UK National Cancer
Data Repository (www.ncin.org.uk), an amalgamated
dataset from the national cancer registries of
England, Wales, Scotland and Northern Ireland. All
non-melanoma skin carcinomas were excluded and only
the ﬁrst cancer for each patient was retained. Cancers
registered only from death certiﬁcate data (DCOs) were
discounted as were diagnoses where the date of death
equalled the date of diagnosis in order to account for
any inconsistencies between recording of DCOs between
regions; 2% of cases for period 1 and 1% of cases for the
two latter periods were excluded. Each case was cen-
sored for follow-up at 31st December 2011 or at earlier
death (from any cause). Follow up is passive.
Information on deaths is routinely received by UK
registries from the relevant government department.
This is added to the records held by the cancer registries.
This system ensures complete follow up of cases with the
exception of migration or rare losses.
Data for Northern Ireland (NI) are available for 1993
onwards only. Cases from NI represent less than 4% of
the overall UK TYA cancer population. Based on data
for 1997–2001 and 2002–2006, we estimated the absence
of one year’s data for NI would have no signiﬁcant
impact on the overall UK survival rates and therefore
decided against using any imputation methods and to
include the full ﬁfteen year period 1992–2006.
Cancer registrations in the UK are classiﬁed using
either the WHO International Classiﬁcation of
Disease, Tenth Revision (ICD-10) or the WHO
International Classiﬁcation of Disease for Oncology
(ICD-O) for site of tumour, along with ICD-O for
tumour morphology. We used morphology codes con-
verted to the second edition of ICD-O (ICD-O2) for
C. O’Hara et al. / European Journal of Cancer 51 (2015) 2039–2048 2041consistency and grouped the diagnoses according to the
standard classiﬁcation for TYA cancers, combining
registered site and morphology codes [12]. Soft tissue
sarcomas were separated into rhabdomyosarcomas
and non-rhabdomyosarcoma soft tissue sarcomas
(NRSTS), since their management diﬀers.
Five-year relative survival was estimated for all can-
cers combined and for each of the eighteen most com-
mon cancers for each ﬁve-year time period (1992–1996,
1997–2001 and 2002–2006). We analysed the population
as a whole, and separately for males and females.
Relative survival was calculated by the Ederer II method
[13] using the strs command developed by the Dickman
lab [14] in a Stata 12 environment. Diﬀerences in excess
mortality at 5 years were tested for three time periods
(1) 1992–1996, (2) 1997–2001 and (3) 2002–2006 using
a multiple regression approach based on generalised lin-
ear models (GLM), assuming a Poisson distribution for
the observed number of deaths [14], including age and
period as covariates. We ﬁtted the poisson regression
model to the grouped data generated by the strs [14]
command. Periods 2 and 3 were separately compared
against period 1 as the baseline. Diﬀerences between
males and females for each period were also tested sep-
arately using a GLM Poisson model including age and
gender as main eﬀects. Time- and gender-related diﬀer-
ences were considered statistically signiﬁcant at
P < 0.05. All statistical analyses were conducted in
Stata version 12.
Average annual percentage changes (AAPC) in
ﬁve-year survival between 1992 and 2006 were calcu-
lated using the ‘Joinpoint’ software [15] with an overall
signiﬁcance level of alpha = 0.05, and a maximum of
two joinpoints [16]. These data are presented for ﬁfteen
of the eighteen cancer types. Three cancer types were
excluded from the analysis because the numbers of cases
and deaths were too small to give meaningful results
(ovarian germ cell tumours (GCTs) and non-gonadal
GCTs) or because survival was consistently high
throughout all study periods (thyroid carcinomas).
International comparisons were based on a literature
search of MEDLINE databases covering the period
2005–2013. We selected publications of 5-year survival
that
(a) were population-based studies using registry data,
(b) provided results for teenagers and young adults as
a separate age category and for males and females
combined, and
(c) covered a time period that overlapped with the
most recent period (2002–06) of our study.
Comparisons were eﬀected on a pragmatic basis
whereby UK rates were considered to be similar to those
of another country if the respective 95% conﬁdence
intervals overlapped. We made no attempt to make
statistical inferences. Our observations should beconsidered in the context of the width of the conﬁdence
intervals and the relative population sizes. Because we
were not able to directly compare 5-year survival
between countries for identical time periods and were
therefore not able to carry out formal statistical compar-
isons, we elected to include only the most recent UK sur-
vival data. More formal comparisons of survival across
Europe have been published for earlier time periods [5].3. Results
3.1. Study subjects
Table 1 shows the number of patients included in the
study by type of cancer and by ﬁve-year period of
diagnosis.3.2. Trends in survival in the UK
Five-year relative survival rates are described in
Table 2 for the three time periods for all cancers com-
bined and for the eighteen most common cancers. For
all cancers combined, survival increased signiﬁcantly
from 75.7% in 1992–1996 to 82.2% in 2002–2006
(P < 0.001) with signiﬁcant improvements in both males
and females.
3.3. Survival by cancer type
Five-year survival varied markedly by cancer group.
There were signiﬁcant improvements in survival between
1992–1996 and 2002–2006 for twelve of the eighteen
cancer types analysed (Fig. 1), including seven with
improvements greater than 10%. Ten cancer types also
had statistically signiﬁcant changes in AAPC over time
(Fig. 2). For Ewing sarcoma and colorectal carcinoma,
although there was a signiﬁcant improvement in survival
between the earliest and latest time periods, the AAPC
was not signiﬁcant; survival improved signiﬁcantly
between periods 1 and 2 but not between periods 2
and 3.
Males had signiﬁcantly worse survival than females
during one or more of the earlier study periods for ﬁve
cancer types: melanomas, CNS tumours (both
P < 0.001), osteosarcomas, Hodgkin lymphomas and
non-gonadal germ cell tumours (all P < 0.05). These dif-
ferences had reduced to a non-signiﬁcant level by 2002–
2006 for all other than melanomas, largely due to
improvements in the survival of male patients rather
than deteriorations in the survival of female patients.
During the most recent period, male patients with
NRSTS also had signiﬁcantly worse survival than
females: the gender diﬀerences had not previously been
signiﬁcantly diﬀerent (Fig. 3). There were no cancer
types for which survival of male patients was better than
survival of female patients.
Table 1
Diagnosis 1992–1996 1997–2001 2002–2006
Persons Males Females Persons Males Females Persons Males Females
n % cases n % cases n % cases n % cases n % cases n % cases n % cases n % cases n % cases
All cancers 8095 100 4262 100 3833 100 8183 100 4465 100 3718 100 9379 100 4954 100 4425 100
ALL 359 4 228 5 131 3 330 4 213 5 117 3 420 4 289 6 131 3
AML 344 4 188 4 156 4 286 3 146 3 140 4 282 3 150 3 132 3
NHL 543 7 341 8 202 5 595 7 372 8 223 6 633 7 389 8 244 6
HL 1352 17 688 16 664 17 1207 15 628 14 579 16 1358 14 693 14 665 15
CNS 1150 14 582 14 568 15 1144 14 598 13 546 15 1286 14 667 13 619 14
Osteosarcoma 200 2 126 3 74 2 213 3 133 3 80 2 206 2 136 3 70 2
Ewing sarcoma 149 2 87 2 62 2 215 3 127 3 88 2 186 2 122 2 64 1
NRSTS 269 3 134 3 135 4 262 3 142 3 120 3 297 3 156 3 141 3
Rhabdomyosarcoma 77 1 57 1 20 1 87 1 61 1 26 1 80 1 53 1 27 1
Testicular GCT 1000 12 1000 23 1176 14 1176 26 1243 13 1243 25
Non-gonadal GCT 82 1 60 1 22 1 86 1 67 2 19 1 101 1 81 2 20 0
Melanoma 834 10 284 7 550 14 849 10 284 6 565 15 1094 12 354 7 740 17
Thyroid carcinoma 327 4 60 1 267 7 299 4 70 2 229 6 446 5 88 2 358 8
Breast carcinoma 113 1 113 3 113 1 113 3 99 1 99 2
Ovarian carcinoma 209 3 209 5 187 2 187 5 233 2 233 5
Cervical carcinoma 153 2 153 4 191 2 191 5 247 3 247 6
Ovarian GCT 92 1 92 2 93 1 93 3 120 1 120 3
Colorectal carcinoma 127 2 65 2 62 2 164 2 76 2 88 2 267 3 138 3 129 3
All other cancer diagnoses 715 8 362 8 353 9 686 8 372 8 314 8 781 8 395 8 386 9
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; GCT, germ cell tumour; CNS, central nervous system tumour;
NRSTS, soft tissue sarcomas excluding rhabdomyosarcoma, GCT, germ cell tumour.
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Table 2
Five year relative survival estimates (%) with 95% conﬁdence intervals (CI) for 15-2 year olds in the UK by period of diagnosis.
Persons Males Females
Diagnosis Period % Survival 95% CI P-value % survival 95% CI P-value % Survival 95% CI P-value
All cancers 1992–1996 75.7 74.8 76.6 73.5 72.1 74.8 78.2 76.8 79.5
1997–2001 78.6 77.7 79.5 <0.001 77.0 75.7 78.2 <0.001 80.6 79.3 81.8 0.005
2002–2006 82.2 81.4 82.9 <0.001 80.6 79.5 81.7 <0.001 83.9 82.8 85.0 <0.001
5-year survival 80-100%
Hodgkin lymphoma 1992–1996 89.8 88.1 91.3 88.5 86.0 90.8 91.2 88.7 93.2
1997–2001 94.1 92.6 95.3 <0.001 92.7 90.3 94.5 0.014 96.1 94.1 97.5 0.001
2002–2006 93.6 92.1 94.8 0.001 93.5 91.4 95.1 0.002 93.7 91.5 95.3 0.090
Ovarian GCT 1992–1996 94.9 87.8 98.1
1997–2001 96.1 89.3 98.7 0.566
2002–2006 93.6 87.4 96.9 0.803
Testicular GCT 1992–1996 93.6 91.9 95.0
1997–2001 95.6 94.2 96.6 0.040
2002–2006 96.5 95.3 97.4 0.001
Non-gonadal GCT 1992–1996 79.4 68.9 86.7 75.1 62.1 84.2 91.3 68.6 98.0
1997–2001 74.6 63.9 82.5 0.606 70.3 57.7 79.7 0.668 89.8 64.3 97.7 0.907
2002–2006 81.3 72.2 87.7 0.708 79.1 68.5 86.5 0.466 90.3 65.8 97.7 0.476
Melanoma 1992–1996 88.7 86.3 90.7 82.2 77.2 86.2 92.0 89.4 94.1
1997–2001 91.0 88.8 92.8 0.078 83.9 79.1 87.7 0.090 94.6 92.3 96.2 0.078
2002–2006 93.7 92.0 95.0 <0.001 88.0 84.1 91.0 <0.001 96.4 94.8 97.6 0.001
Thyroid carcinoma 1992–1996 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
1997–2001 99.7 97.7 100.0 0.996 97.3 89.2 99.4 0.999 100.0 100.0 100.0 0.999
2002–2006 99.0 97.3 99.7 0.996 96.7 89.9 99.0 0.999 99.5 97.8 100.0 0.999
Breast carcinoma 1992–1996 67.6 58.0 75.4
1997–2001 70.2 60.8 77.8 0.706
2002–2006 82.1 73.0 88.5 0.015
Cervical carcinoma 1992–1996 79.4 72.1 85.1
1997–2001 87.3 81.6 91.3 0.046
2002–2006 87.8 82.9 91.3 0.027
5-year survival 50–80%
ALL 1992–1996 44.7 39.5 49.7 45.2 38.7 51.6 43.7 35.0 52.0
1997–2001 50.7 45.2 56.0 0.148 51.7 44.8 58.2 0.149 48.9 39.5 57.6 0.351
2002–2006 62.0 57.2 66.5 <0.001 62.4 56.5 67.7 <0.001 61.2 52.3 69.0 0.002
AML 1992–1996 43.7 38.4 48.9 43.7 36.5 50.6 43.8 35.9 51.4
1997–2001 48.7 42.8 54.4 0.070 47.3 39.0 55.2 0.070 50.2 41.6 58.2 0.111
2002–2006 60.4 54.4 65.9 <0.001 60.1 51.8 67.4 <0.001 60.8 51.9 68.6 0.001
NHL 1992–1996 66.3 62.1 70.1 67.0 61.7 71.7 65.1 58.1 71.3
1997–2001 71.8 68.0 75.2 0.043 70.0 65.0 74.4 0.045 74.7 68.5 80.0 0.023
2002–2006 78.4 74.9 81.4 <0.001 79.0 74.6 82.8 <0.001 77.3 71.5 82.1 0.002
CNS 1992–1996 75.4 72.8 77.8 71.2 67.4 74.7 79.7 76.1 82.8
1997–2001 73.3 70.6 75.7 0.249 70.0 66.1 73.5 0.289 76.9 73.1 80.2 0.215
2002–2006 79.3 77.0 81.5 0.015 77.6 74.2 80.6 0.011 81.2 77.9 84.1 0.538
(continued on next page)
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Table 2 (continued)
Persons Males Females
Diagnosis Period % Survival 95% CI P-value % survival 95% CI P-value % Survival 95% CI P-value
Osteosarcoma 1992–1996 50.6 43.5 57.3 43.7 34.9 52.1 62.4 50.3 72.4
1997–2001 49.4 42.5 55.9 0.874 48.2 39.5 56.4 0.928 51.4 40.0 61.7 0.167
2002–2006 54.0 46.9 60.5 0.488 50.1 41.4 58.1 0.447 61.6 49.1 71.9 0.975
NRSTS 1992–1996 56.7 50.5 62.4 54.6 45.7 62.5 58.8 49.9 656.6
1997–2001 68.5 62.5 73.8 0.003 63.5 55.0 70.8 0.122 74.4 65.6 81.4 0.005
2002–2006 66.8 61.1 71.9 0.009 61.6 53.5 68.8 0.210 72.6 64.4 79.2 0.010
Ovarian carcinoma 1992–1996 81.2 75.2 86.0
1997–2001 76.8 70.0 82.3 0.249
2002–2006 79.7 73.9 84.4 0.78
Colorectal carcinoma 1992–1996 57.6 48.5 65.7 53.9 41.1 65.1 61.5 48.2 72.4
1997–2001 68.5 60.8 75.0 0.052 61.9 50.0 71.8 0.059 74.2 63.6 82.1 0.119
2002–2006 68.0 62.0 73.2 0.023 66.8 58.2 74.0 0.020 69.2 60.5 76.5 0.265
5-year survival <50%
Ewing sarcoma 1992–1996 33.0 25.6 40.6 29.9 20.7 39.7 37.2 25.4 49.1
1997–2001 45.2 38.5 51.7 0.006 41.8 33.1 50.2 0.006 5.2 39.3 60.1 0.061
2002–2006 45.8 38.5 52.8 0.005 44.3 35.4 52.9 0.004 48.6 35.9 60.1 0.099
Rhabdomyosarcoma 1992–1996 27.3 17.9 37.6 24.6 14.4 36.3 35.1 15.7 55.4
1997–2001 24.2 15.8 33.6 0.964 21.3 12.1 32.3 0.802 30.9 14.7 48.7 0.378
2002–2006 35.1 24.8 45.5 0.109 39.7 26.6 52.5 0.156 26.0 11.5 43.2 0.234
ALL, acute lymphoblastic leukameia; AML, acute myeloid leukaemia; NHL, non-Hodgkin lymphoma; GCT, germ cell tumour; CNS, central nervous system tumour; NRSTS, non-rhab-
domyosarcoma soft tissue sarcomas, CI, conﬁdence interval. P-value for excess hazard ratios comparing period 2 (1997–2001) with period 1 (1992–1996) and period 3 (2002–2006) with period 1.
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** Testicular GCT
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** HL
* CNS
*** Melanoma
Rhabdomyosarcoma
* Cervical carcinoma
** NRSTS
* Colorectal carcinoma
*** NHL
** Ewing sarcoma
* Breast carcinoma
*** AML
*** ALL
Difference in 5-year survival period 1 to period 3 
Fig. 1. Diﬀerences in 5-year survival for all persons between 1992–
1996 and 2002–2006. Signiﬁcance is indicated as *P < 0.05, **P < 0.01,
***P < 0.001. Error bars represent 95% conﬁdence intervals. Thyroid
carcinoma is excluded as baseline survival was already 100%. ALL,
acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; NHL,
non-Hodgkin lymphoma; HL, Hodgkin lymphoma; GCT, germ cell
tumour; CNS, central nervous system tumour; NRSTS, soft tissue
sarcomas excluding rhabdomyosarcomas.
*** 
*** 
* 
*** 
* 
* 
** *** 
* * 
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C 
Fig. 2. Annual average percentage change (AAPC) 1992–2006.
Signiﬁcance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001. ALL,
Acute lymphoblastic leukaemia; AML, acute myeloid leukaemia;
NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; GCT, germ
cell tumour; CNS, central nervous system tumour; NRSTS, soft tissue
sarcomas excluding rhabdomyosarcomas.
* 
* 
*** 
** 
*** 
*** 
*** 
* 
* 
-0.5 0 0.5 1 1.5 2 2.5 3
Rhabdomyosarcoma
Ewing sarcoma
Colorectal carcinoma
NRSTS
Osteosarcomas
CNS
NHL
AML
ALL
Melanoma
Non-gonadal GCT
Hodgkin lymphoma
Excess hazard ratio 
1992-1996 
1997-2001 
2002-2006 
Fig. 3. Excess hazard ratios for females compared with males for each
time period and disease group. Error bars represent 95% conﬁdence
intervals. ALL, acute lymphoblastic leukaemia; AML, acute myeloid
leukaemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma;
GCT, germ cell tumour; CNS, central nervous system tumour;
NRSTS, soft tissue sarcomas excluding rhabdomyosarcomas.
Signiﬁcance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001.
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Survival for all major haematological malignancies
increased signiﬁcantly between 1992–1996 and 2002–
2006. The annual average percentage increase for leu-
kaemia was the highest among all TYA cancers at
3.2% for ALL and 3.9% for AML. Most improvement
occurred between 1997–2001 and 2002–2006. Five-year
survival also increased signiﬁcantly between the earliest
and latest periods for NHL and Hodgkin lymphoma.
3.5. CNS tumours
There were no signiﬁcant changes in survival rates for
either males or females with CNS tumours between1992–1996 and 1997–2001. However, survival of male
patients did increase signiﬁcantly between 1997–2001
and 2002–2006, giving an overall improvement of 3.9%
for all persons. Females maintained signiﬁcantly better
survival than males throughout the study period.3.6. Bone tumours
Survival from Ewing sarcoma increased signiﬁcantly
between 1992–1996 and 2002–2006, most of the
improvement being seen in males. Survival for osteosar-
coma did not change signiﬁcantly.3.7. Soft tissue sarcomas
For NRSTS, survival improved signiﬁcantly by
10.1%, the improvement limited to the period between
1992–1996 and 1997–2001. In contrast, survival from
rhabdomyosarcoma did not signiﬁcantly change,
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between the latter two study periods. There was an
apparent reversal of gender diﬀerences in survival
from rhabdomyosarcoma between the earliest and latest
periods but the diﬀerences remained non-signiﬁcant
(Fig. 3).
3.8. Germ cell tumours
Survival for patients with testicular GCT increased
signiﬁcantly from 93.6% in 1992–1996 to 96.5% in
2002–2006. There were no signiﬁcant changes in the
survival of ovarian GCT or non-gonadal GCT.3.9. Melanoma
Survival increased signiﬁcantly by 5.0% for mela-
noma over the whole study period. Females maintained
better survival than males throughout the entire period.3.10. Carcinomas
Survival for breast carcinoma in females increased
signiﬁcantly by 2.4% per year and by 14.5% overall,
mostly in the latter half of the study period. Survival
for cervical carcinoma and colorectal carcinoma rose
signiﬁcantly by 8.4% and 10.4% respectively, predomi-
nantly in the ﬁrst half of the study period. The improve-
ment in colorectal carcinoma was more marked in males
than females. There were no signiﬁcant changes in
survival of thyroid cancer or ovarian carcinoma.3.11. International comparisons
Table 3 shows ﬁve-year survival rates from our study
for 2002–2006 alongside reports for eight other popula-
tions in Europe, USA, Canada and Australia. One
paper from the Netherlands [17] presented for males
and females separately and the data were therefore not
shown.
Five-year survival for the UK was similar to other
populations for most types of cancer, although some
results may warrant further investigation. The most
recent cancer survival data for adolescents and young
adults in the USA were published by Bleyer and col-
leagues [18]. These data were based on cancer registra-
tion data for 15–39 olds over the period 1985–2007.
The results were generally similar to ours, with particu-
larly large survival improvements in ALL and AML.
UK data showed greater AAPC than US data for
Ewing sarcoma (2.46 versus 0.75) and for breast
carcinoma (2.37 versus 0.75). In contrast, ﬁve-year UK
survival of osteosarcoma was 10–15% lower than for
the USA [9,10] and for Germany [9]. Survival also
appeared to be higher in Germany than in the UK for
Hodgkin lymphoma and melanoma.
C. O’Hara et al. / European Journal of Cancer 51 (2015) 2039–2048 20474. Discussion
Considerable improvements in ﬁve-year survival have
been made for TYA patients in the UK since the early
1990s. In particular, we report here signiﬁcant improve-
ments in outcome for twelve of the eighteen types of
cancer that make up the majority of TYA cancer in
the UK. Improvements in survival were generally more
marked between the latter two periods than the earlier
two. We have not looked in this report at the factors
that may underlie these observed improvements.
However, the study periods we report here have encom-
passed several major changes in treatment that may
have aﬀected survival outcomes in TYA cancers. For
instance, there has been a major shift in the treatment
of acute lymphoblastic leukaemia in this age group from
an ‘adult’ treatment strategy to a ‘paediatric’ treatment
strategy following the publication of several reports of
diﬀerential survival in adolescents treated according to
paediatric strategies [19].
In addition, there have been several centrally driven
initiatives that may have impacted on survival. The
Calman-Hine report was published in 1995, at the end
of the ﬁrst period reported here, and made several key
recommendations for the delivery of cancer diagnosis
and care, with speciﬁc reference to the care of children
and adolescents with cancer, and the role of specialised
care for rare cancers [20]. The 1990s and 2000s saw the
development of specialist TYA cancer centres in most
major cities, aﬃliated with major cancer centres.
Finally, the development of TYA multidisciplinary
teams (MDTs) with both age and disease specialisation
have played a central role in the management of many
adolescent and young adult patients. The pivotal role
of the TYA MDT was recognised in its inclusion as a
core component in the delivery of cancer care in the
national guidance for young people with cancer [11].
Nevertheless, areas of concern persist, particularly the
apparent stasis in outcome ﬁgures for ovarian carci-
noma, ovarian GCT, non-gonadal GCT, rhab-
domyosarcoma and osteosarcoma. For some of the
key malignancies characteristic of the adolescent and
young adult years, bone sarcomas and alveolar rhab-
domyosarcomas, overall survival remains around or
under 50%. Moreover, there remains a survival gap
between genders for some cancers.
The international data we discuss vary in terms of
population sizes, age ranges, time periods, data col-
lection methods, population coverage and survival
analysis methods. The age range focus in particular
is likely to inﬂuence apparent diﬀerences. Survival
for ALL and to a lesser extent AML decreases with
increasing age [6] which may partly explain the
higher survival observed for ALL among 15–24 year
olds in the UK compared with the 15–39 age group
in the USA [18].Survival for osteosarcoma in the USA [9,10] and
Germany [9] was considerably higher than for the UK;
in fact osteosarcoma had the largest percentage diﬀer-
ence compared with the UK for any type of cancer in
each of these three studies. Since the early 1980s much
of North West Europe performed collaborative clinical
trials in osteosarcoma under the auspices of the
European Osteosarcoma Intergroup (EOI) or the
Cooperative German-Austrian-Swiss Osteosarcoma
Study Group (COSS). During the earlier time periods
we report here, the chemotherapy regimens used by
the EOI and COSS groups were diﬀerent. Towards the
end of the latter period both groups collaborated under
the EURAMOS collaboration [21,22] and used the same
chemotherapy protocols and it is of concern that TYA
patients with osteosarcoma in the UK appear to have
worse outcomes than those treated in Germany.
Diﬀerences in diagnostic inclusion criteria are likely
to have contributed to some of the variation seen in
the comparison with UK and international data.
Non-malignant CNS tumours were included in our
study but were excluded from several others (e.g.
[5,18]), therefore the results are not directly comparable.
UK cancer statistics generally include benign and bor-
derline CNS tumours since, although not malignant,
such tumours are responsible for a considerable number
of deaths. Diﬀerences may also arise as a result temporal
variations in the diagnostic classiﬁcation systems used:
for instance, pilocytic astrocytomas had a malignant
behaviour code in ICD-O-2 but are now classiﬁed as
non-malignant in ICD-O-3. Further comparative studies
will be needed to accurately quantify international dif-
ferences in survival, based on common protocols such
as those undertaken by EUROCARE and
CONCORD [23] but with a focus on speciﬁc tumour
types. Future comparative studies would be strength-
ened by focusing on the relationships between service
provision, including issues such as where patients are
treated, clinical disease management and survival.
It is hoped that recent policy changes for TYA cancer
services in the UK will impact on the outcomes, includ-
ing survival outcomes, of young cancer patients. These
improvements may be particularly marked in the rarer
tumours considered to beneﬁt most from age- or
disease-specialist care. The data we report here set a
baseline for future comparisons. We have conﬁned our
analysis to patients aged 15–24 in recognition that this
age group is particularly vulnerable to falling in a gap
between paediatric and adult health services, but
acknowledge that selection of this age range may be
more meaningful for some health systems and types of
cancer than others.
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